TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10230146

Group type: EXPERIMENTAL
Intervention: System of care
Number of subjects: 350

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: No services
Number of subjects: 350
Study: 8966308

Group type: EXPERIMENTAL
Intervention: Pentamidine 4 mg/kg/every 2 days for 8 applications
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Aminosidine 20 mg/kg/day for 20 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Meglumine 10 mg Sbv/kg/day for 20 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Follow-up after 3 years
Number of subjects: 46
Study: 1898891

Group type: EXPERIMENTAL
Intervention: Low-dose follicle-stimulating hormone (FSH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose human menopausal gonadotropin (hMG)
Number of subjects: 30
Study: 6331270

Group type: EXPERIMENTAL
Intervention: Ranitidine (40 mg X 3 daily and 80 mg at bedtime)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31112494

Group type: EXPERIMENTAL
Intervention: Onetime home nurse visit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent recall of reutilization events
Number of subjects: 0
Study: 29558967

Group type: EXPERIMENTAL
Intervention: Juanbi pill
Number of subjects: 120
Study: 26423446

Group type: EXPERIMENTAL
Intervention: Weight loss achieved with reduced energy intake and increased physical activity (PA) for 0-6 months; maintenance provided adequate energy to maintain weight and continued PA for 7-18 months
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Self-efficacy for weight management and exercise barriers
Number of subjects: 359
Study: 24768543

Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (2.0g)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous Tranexamic Acid (10mg/kg)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid
Number of subjects: 89
Study: 23159258

Group type: EXPERIMENTAL
Intervention: 4 kcal/kg per week aerobic training
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 8 kcal/kg per week aerobic training
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 12 kcal/kg per week aerobic training
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 325
Study: 20051288

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose 200 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral ferrous sulphate 600 mg/day
Number of subjects: 44
Study: 18081185

Group type: EXPERIMENTAL
Intervention: SOMA Safe Enclosure
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard Restraints
Number of subjects: 49
Study: 17265577

Group type: EXPERIMENTAL
Intervention: Simplified version of the HIV vaccine process
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard version of the HIV vaccine process
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Both versions (simplified and standard)
Number of subjects: 187
Study: 14973564

Group type: EXPERIMENTAL
Intervention: Miswak (chewing stick)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Miswak extract (50% solution)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Miswak
Number of subjects: 40
Study: 10637236

Group type: EXPERIMENTAL
Intervention: HAI 5‐FU/LV
Number of subjects: 168

Group type: COMPARATOR
Intervention: IV 5‐FU/LV
Number of subjects: 168

Group type: COMPARATOR
Intervention: HAI FUDR
Number of subjects: 168
Study: 9156505

Group type: EXPERIMENTAL
Intervention: Myrtol standardized
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Other essential oil
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 8471679

Group type: EXPERIMENTAL
Intervention: Oxaprotiline (a highly specific inhibitor of NA uptake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levoprotiline (devoid of NA uptake property)
Number of subjects: 0
Study: 3896016

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cosalgesic (dextropropoxyphene hydrochloride 65 mg and paracetamol 650 mg)
Number of subjects: 57
Study: 11277684

Group type: EXPERIMENTAL
Intervention: Current SLT use
Number of subjects: 7865

Group type: EXPERIMENTAL
Intervention: Past SLT use
Number of subjects: 7865
Study: 31351445

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation with volume guaranteed mode (PCV-VG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Volume-controlled ventilation mode (VCV)
Number of subjects: 36
Study: 29739384

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (CBT) intervention plus Treatment as Usual (TAU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study: 27498652

Group type: EXPERIMENTAL
Intervention: Dr Michaels® (Soratinex®) herbal skin-care products
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (neutral ointments and medicinal bathing oil)
Number of subjects: 142
Study: 24916165

Group type: EXPERIMENTAL
Intervention: Iron supplementation (50 mg Fe as FeSO₄, 4 days/week for 38 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 73
Study: 22257480

Group type: EXPERIMENTAL
Intervention: ilaprazole 5mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ilaprazole 10mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ilaprazole 20mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: omeprazole 20mg
Number of subjects: 12
Study: 19152958

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo to Duloxetine 60 mg/d
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo to Duloxetine 120 mg/d
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 482
Study: 17482343

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 148
Study: 16278493

Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 11879862

Group type: EXPERIMENTAL
Intervention: 5 mg/day enalapril for 2 years
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 26
Study: 10439732

Group type: EXPERIMENTAL
Intervention: Rapacuronium 1 mg/kg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rapacuronium 2 mg/kg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rapacuronium 3 mg/kg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study: 7486464

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal-conjugate vaccine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HIB-conjugate vaccine
Number of subjects: 144
Study: 2240380

Group type: EXPERIMENTAL
Intervention: Aminoglycosides
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (not receiving aminoglycosides)
Number of subjects: 292
Study: 323297

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium phosphate (40, 80, or 160 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium phosphate (80 mg, multiple doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (same doses as methylprednisolone sodium phosphate)
Number of subjects: 36
Study: 30886732

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg two times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg two times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29205786

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg subcutaneous dose
Number of subjects: 44
Study: 27521353

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) for 2 weeks
Number of subjects: 814

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 814
Study: 25031362

Group type: EXPERIMENTAL
Intervention: Personal safety awareness program
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study: 22178855

Group type: EXPERIMENTAL
Intervention: injectable trace mineral supplement (ITM; n = 42; 7 mL subcutaneous; MultiMin, Fort Collins, CO)
Number of subjects: 99

Group type: COMPARATOR
Intervention: saline‐injected control (Control; n = 42)
Number of subjects: 99
Study: 19957034

Group type: EXPERIMENTAL
Intervention: Fusion short‐wire system
Number of subjects: 71
Study: 17385061

Group type: EXPERIMENTAL
Intervention: 5 g resistant maltodextrin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 g resistant maltodextrin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (beverage not containing resistant maltodextrin)
Number of subjects: 13
Study: 16343383

Group type: EXPERIMENTAL
Intervention: Viatim (combined hepatitis A and typhoid fever vaccine)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Monovalent HA vaccine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Monovalent Vi vaccine
Number of subjects: 360
Study: 12631173

Group type: EXPERIMENTAL
Intervention: Anaesthetic gel (Oraqix) containing 25 mg/g prilocaine and 25 mg/g lidocaine, applied for 30 seconds prior to periodontal debridement.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo gel, applied for 30 seconds prior to periodontal debridement.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Anaesthetic gel (Oraqix)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 130
Study: 10642370

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution (C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate + 4.2% MCT solution (C+M)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sweet placebo (P)
Number of subjects: 8
Study: 8891962

Group type: EXPERIMENTAL
Intervention: Acute trauma patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (same‐day elective surgery patients)
Number of subjects: 11
Study: 2068469

Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g intravenously 30 minutes before surgery and 8 and 16 hours after surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gentamicin (80 mg intravenously 30 minutes before surgery and 8 and 16 hours after surgery)
Number of subjects: 80
Study: 6859471

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study: 30888478

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg daily for 6 months
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 29513659

Group type: EXPERIMENTAL
Intervention: Non-targeted screening arm
Number of subjects: 160

Group type: COMPARATOR
Intervention: Targeted testing arm
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Targeted arm after cross-screening
Number of subjects: 160

Group type: COMPARATOR
Intervention: Acceptance rate in targeted arm
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Acceptance rate in non-targeted arm
Number of subjects: 160
Study: 27591157

Group type: EXPERIMENTAL
Intervention: PID‐C (Personalized Intervention for Depressed Patients with COPD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: PSA (Problem Solving‐Adherence)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (Usual Care)
Number of subjects: 101
Study: 25198265

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pyridoxine (25 mg) plus Doxylamine (12.5 mg)
Number of subjects: 36
Study: 22475593

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (180 mg pyronaridine and 60 mg artesunate, administered once daily for 3 days)
Number of subjects: 1271

Group type: COMPARATOR
Intervention: Mefloquine plus artesunate (250 mg mefloquine and 100 mg artesunate, administered once daily for 3 days)
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 1271

Group type: COMPARATOR
Intervention: Mefloquine plus artesunate
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1271
Study: 20813564

Group type: EXPERIMENTAL
Intervention: 25% podophyllin resin with 5% acyclovir cream (PA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 25% podophyllin resin (P)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 25% podophyllin resin with 1% penciclovir cream (PP)
Number of subjects: 42
Study: 18089329

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 127

Group type: COMPARATOR
Intervention: Daclizumab
Number of subjects: 127
Study: 16258087

Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily for 5 years)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Control (no additional treatment)
Number of subjects: 829
Study: 11849730

Group type: EXPERIMENTAL
Intervention: Bright light (5000 lux for 5 h from 00:00 to 05:00 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dim light (10 lux for 5 h from 00:00 to 05:00 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bright light
Number of subjects: 9
Study: 9489596

Group type: EXPERIMENTAL
Intervention: Frusemide 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Frusemide 25 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg
Number of subjects: 5
Study: 8172095

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)2D) treatment (1 micrograms/d for 4 d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)2D) treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3351700

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous metoclopramide
Number of subjects: 22
Study: 31436322

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (nCT) with cisplatin 100 mg/m2 on day 1 and 750 mg/m2 5-fluorouracil over 24 hours on days 1-5 for three 21-day cycles
Number of subjects: 165

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) with the same chemotherapy regimen plus 40 Gy radiotherapy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (nCT)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both nCT and nCRT
Number of subjects: 165
Study: 30563808

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention with Fitbit integration
Number of subjects: 243

Group type: COMPARATOR
Intervention: Web-based computer-tailored intervention without Fitbit integration (Control)
Number of subjects: 243
Study: 26382634

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24473436

Group type: EXPERIMENTAL
Intervention: recombinant human IL-6 (rhIL-6)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 23171567

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), n = 60, energy dose of 6 J per tender point, treated three times per week for four weeks (total of 12 sessions).
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CLLLT), n = 60, treated three times per week for four weeks (total of 12 sessions).
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), n = 60.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CLLLT), n = 60.
Number of subjects: 120
Study: 20631462

Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 (two injections, 2 weeks apart, n = 150)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Methylprednisolone acetate (MPA) (1 injection of 40 mg and 1 sham injection 2 weeks later, n = 155)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20
Number of subjects: 313

Group type: COMPARATOR
Intervention: Methylprednisolone acetate (MPA)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 and MPA
Number of subjects: 313
Study: 17397005

Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP) for CIN3 treatment
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: HPV16 non-European variants
Number of subjects: 201
Study: 15105817

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 20‐25 mg of triamcinolone acetonide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intravitreal injection)
Number of subjects: 28
Study: 12498843

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Poly(methyl methacrylate) IOL (PMMA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified PMMA (HSM PMMA) IOL
Number of subjects: 140
Study: 9834303

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Aspirin and warfarin
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 1653
Study: 8014643

Group type: COMPARATOR
Intervention: Anatomic Modular Knee (AMK)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Miller Galante I (MG I)
Number of subjects: 100
Study: 2674744

Group type: EXPERIMENTAL
Intervention: Hypoglycemia-induced somatotropin (STH) secretion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous administration of luliberin
Number of subjects: 24
Study: 5675432

Group type: EXPERIMENTAL
Intervention: Aspirin (1.5 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspirin (0.50 mmole/liter)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspirin (1.8 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium salicylate
Number of subjects: 6
Study: 6777458

Group type: EXPERIMENTAL
Intervention: Clovoxamine 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clovoxamine 75 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clovoxamine 125 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 75 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31813228

Group type: EXPERIMENTAL
Intervention: Lay counselor-delivered problem-solving therapy
Number of subjects: 19
Study: 29932584

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound rectus sheath block of ropivacaine with systemic analgesia
Number of subjects: 58

Group type: COMPARATOR
Intervention: Only systemic analgesia
Number of subjects: 58
Study: 25680658

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study: 23588864

Group type: EXPERIMENTAL
Intervention: Tramadol (200 mg added to treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transdermal fentanyl (TDF) (initial dose of 25 µg/h, increased by 25 µg/h as needed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (Group K)
Number of subjects: 0
Study: 20924769

Group type: EXPERIMENTAL
Intervention: Stand-alone PEEK cages
Number of subjects: 72

Group type: COMPARATOR
Intervention: Iliac crest autografts
Number of subjects: 72
Study: 19065670

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Adefovir 10 mg/day
Number of subjects: 69
Study: 17596805

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine, trivalent (CAIV-T)
Number of subjects: 3174
Study: 15099138

Group type: EXPERIMENTAL
Intervention: Change in font and case during study and test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance of a secondary task during study
Number of subjects: 0
Study: 11231746

Group type: EXPERIMENTAL
Intervention: Internet behavior therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Internet education
Number of subjects: 91
Study: 9854458

Group type: EXPERIMENTAL
Intervention: Octreotide (subcutaneous)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7840403

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 57

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 57

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nalbuphine
Number of subjects: 57
Study: 2966565

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sequential intravenous streptokinase and PTCA
Number of subjects: 200

Group type: COMPARATOR
Intervention: rt-PA alone
Number of subjects: 200

Group type: COMPARATOR
Intervention: rt-PA followed by immediate angioplasty
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase with angioplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: rt-PA with angioplasty
Number of subjects: 200
Study: 30550415

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise program
Number of subjects: 264
Study: 31243560

Group type: EXPERIMENTAL
Intervention: CISB + GA
Number of subjects: 85

Group type: COMPARATOR
Intervention: GA
Number of subjects: 85
Study: 28682922

Group type: EXPERIMENTAL
Intervention: Aerobic exercise session (treadmill; 40 min; 55% VO2peak)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 109
Study: 25937505

Group type: EXPERIMENTAL
Intervention: Enhanced screening and referral using an electronic psychosocial screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mentoring using the prioritization tool
Number of subjects: 0